Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $245 from $260 and keeps an Equal Weight rating on the shares. The firm reduced estimates to reflect revised assumptions for life science growth in the second half of 2025 and 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
- Bio-Rad Laboratories Balances Growth and Challenges in Q1 2025 Earnings Call
- Bio-Rad price target lowered to $310 from $355 at UBS
- Bio-Rad price target lowered to $350 from $400 at Citi
- Bio-Rad Laboratories Reports Q1 2025 Financial Results
- Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%